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Abstract
Background: Sleep-disordered breathing is a common condition associated with adverse health outcomes including
hypertension and cardiovascular disease. The overall objective of this study was to determine whether sleep-disordered
breathing and its sequelae of intermittent hypoxemia and recurrent arousals are associated with mortality in a community
sample of adults aged 40 years or older.
Methods and Findings: We prospectively examined whether sleep-disordered breathing was associated with an increased
risk of death from any cause in 6,441 men and women participating in the Sleep Heart Health Study. Sleep-disordered
breathing was assessed with the apnea–hypopnea index (AHI) based on an in-home polysomnogram. Survival analysis and
proportional hazards regression models were used to calculate hazard ratios for mortality after adjusting for age, sex, race,
smoking status, body mass index, and prevalent medical conditions. The average follow-up period for the cohort was 8.2 y
during which 1,047 participants (587 men and 460 women) died. Compared to those without sleep-disordered breathing
(AHI: ,5 events/h), the fully adjusted hazard ratios for all-cause mortality in those with mild (AHI: 5.0–14.9 events/h),
moderate (AHI: 15.0–29.9 events/h), and severe (AHI: $30.0 events/h) sleep-disordered breathing were 0.93 (95% CI: 0.80–
1.08), 1.17 (95% CI: 0.97–1.42), and 1.46 (95% CI: 1.14–1.86), respectively. Stratified analyses by sex and age showed that the
increased risk of death associated with severe sleep-disordered breathing was statistically significant in men aged 40–70 y
(hazard ratio: 2.09; 95% CI: 1.31–3.33). Measures of sleep-related intermittent hypoxemia, but not sleep fragmentation, were
independently associated with all-cause mortality. Coronary artery disease–related mortality associated with sleep-
disordered breathing showed a pattern of association similar to all-cause mortality.
Conclusions: Sleep-disordered breathing is associated with all-cause mortality and specifically that due to coronary artery
disease, particularly in men aged 40–70 y with severe sleep-disordered breathing.
Please see later in the article for the Editors’ Summary.
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Introduction
Sleep-disordered breathing is being increasingly recognized as a
cause of substantial morbidity and mortality. Characterized by
recurrent collapse of the upper airway, sleep-disordered breathing
is associated with recurrent episodes of intermittent hypoxemia
and arousals from sleep. Approximately 9% of women and 24% of
men in the general population have sleep-disordered breathing
and a majority of those affected remain undiagnosed [1]. In
addition to causing excessive daytime sleepiness and impaired
quality of life [2], sleep-disordered breathing has been implicated
in increasing all-cause and cause-specific mortality. Evidence from
clinic-based studies suggests that patients with sleep-disordered
breathing have a higher mortality risk and that treatment with
positive airway pressure during sleep may attenuate this risk [3–
19]. However, previous studies based on clinical samples have
yielded inconsistent results, possibly due to methodological
limitations including small sample sizes and use of select patient
samples. Furthermore, some of the earlier studies failed to
adequately consider potential confounding by obesity and factors
such as prevalent hypertension and cardiovascular disease. Recent
data from two population-based cohort studies with modest
sample sizes have shown that even after accounting for such
confounders, sleep-disordered breathing is independently associ-
ated with all-cause mortality [20,21].
The effects of sleep-disordered breathing on mortality may be
mediated in part by its association with other medical conditions
including hypertension, coronary artery disease (CAD), congestive
heart failure, and stroke [22]. Despite the increased burden of
adverse health outcomes, epidemiologic information on all-cause
and cause-specific mortality in sleep-disordered breathing is
limited and uncertainty remains regarding effect modification by
other factors. For example, it is not known whether the association
between sleep-disordered breathing and mortality varies with age
and sex. In addition, little is known about the role of intermittent
hypoxemia and sleep disruption, the two characteristic features of
sleep-disordered breathing, in mediating the association between
sleep-disordered breathing and mortality. Previous work from the
Sleep Heart Health Study has shown that sleep-related intermit-
tent hypoxemia is associated with prevalent hypertension, CAD,
heart failure, and stroke [23–25]. Thus, the degree of intermittent
hypoxemia and sleep disruption may also predict all-cause and
cause-specific mortality. In the current report, we present
longitudinal data collected by the Sleep Heart Health Study, a
study of the cardiovascular consequences of sleep-disordered
breathing, and examine whether this chronic condition is
independently associated with mortality and evaluate the possible
effects of sex and age on this association. Secondary objectives
included assessment of whether the degree of sleep-related
intermittent hypoxemia and frequency of arousals in sleep-
disordered breathing are associated with an increased risk of
mortality.
Methods
Study Design and Population
The Sleep Heart Health Study is a prospective cohort study of
cardiovascular consequences of sleep-disordered breathing. Details
of the study design have been reported previously [26]. Briefly,
between 1995 and 1998 participants were recruited from
prospective cohort studies including the Framingham Offspring
and Omni Study, the Atherosclerosis Risk in Communities Study,
the Cardiovascular Health Study, the Strong Heart Study, and the
cohort studies of respiratory disease in Tucson and of hypertension
in New York. Eligible individuals were at least 40 years of age and
were not being treated for sleep-disordered breathing with positive
airway pressure, oral appliance, oxygen, or tracheostomy. A total
of 6,441 participants completed the baseline examination and
constitute the analysis sample for this report. Each participant in
the Sleep Heart Health Study provided written consent and the
study protocol was approved by the institutional review board of
each participating field site.
Data Collection
Each participant completed a baseline examination that
included a detailed health interview, full-montage unattended
home polysomnogram, measurements of blood pressure and
anthropometry, as well as assessments of sleep habits and
prescription medication use. Prevalent cardiovascular disease
was defined as history of physician-diagnosed angina, heart
failure, myocardial infarction, stroke, and coronary revasculariza-
tion, and was determined by adjudicated surveillance data
provided by the parent cohorts or by self-report at enrollment.
Information on covariates, such as smoking, was obtained by self-
report. Anthropometric measures including weight, height, neck
circumference, and waist girth were obtained along with three
measurements of resting blood pressure during the night of the
sleep study by trained and certified technicians.
The sleep study was conducted using a portable monitor (P-
Series, Compumedics, Abbotsville, AU). The following signals
were recorded: C3/A1 and C4/A2 electroencephalograms, bilat-
eral electrooculograms, a single bipolar electrocardiogram, a chin
electromyogram, oxyhemoglobin saturation by pulse oximetry,
chest and abdominal excursion by inductance plethysmography,
airflow by an oronasal thermocouple, and body position by a
mercury gauge. Details of polysomnographic equipment, hook-up
procedures, failure rates, scoring, and quality assurance and
control have been published [27]. Apneas were identified if airflow
was absent or nearly absent for at least 10 s. Hypopneas were
identified when there was at least 30% reduction in airflow or
thoracoabdominal movement for at least 10 s. Apneas were
further classified as obstructive if movement on either the chest or
abdominal inductance channels was noted, or as central if no
displacement was observed on both of these channels. No attempt
was made to classify hypopneas as obstructive or central. The
apnea–hypopnea index (AHI) was defined as the number of
apneas and hypopneas, each associated with a 4% or greater
decrease in oxygen saturation, per hour of sleep. An arousal index
was defined as the average number of arousals per hour of sleep
according to standard criteria [28]. Additional metrics of sleep-
disordered breathing severity derived from the sleep study
included the percentage of total sleep time with oxyhemoglobin
saturation below 90% (TST90) and the central apnea index (i.e.,
the number of central apneas per hour of sleep).
Deaths from any cause, the primary endpoint for this report,
were identified and confirmed for the cohort using multiple
concurrent approaches including follow-up interviews, written
annual questionnaires or telephone contacts with study partici-
pants or next-of-kin, surveillance of local hospital records and
community obituaries, and linkage with the Social Security
Administration Death Master File. Using these methods, 1,047
deaths were identified in the incident cohort with a censoring date
of April 1, 2006. During the follow-up period, 147 participants
reported treatment with positive airway pressure, an oral
appliance, supplemental oxygen, or an open tracheostomy.
Sensitivity analyses with exclusion of these participants showed
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that estimates of mortality risk associated with sleep-disordered
breathing remained materially unchanged. Thus, analyses that
exclude these participants are reported herein.
Statistical Analysis
Mortality rates were calculated by dividing number of deaths by
number of person–years at risk accumulated. The AHI was
categorized using commonly used clinical cutoff points:,5 (normal),
5.0–14.9 (mild disease), 15.0–29.9 (moderate disease), and $30.0
events/h (severe disease). In addition, quartile-based cutoff points
were also used to categorize the AHI. Sensitivity analyses showed that
inferences regarding the association between sleep-disordered
breathing severity and mortality were similar regardless of whether
clinical or quartile-based thresholds of AHI were used. Thus, the AHI
was modeled as a categorical variable using the above clinical cutoff
points. Other indicators of sleep-disordered breathing severity (e.g.,
arousal frequency) were grouped into quartiles. Because TST90 and
the central apnea index were heavily skewed, each variable was
dichotomized using the 75th percentile as the cutoff point. In addition,
continuous forms of TST90 and the central apnea index were also
examined as predictors of mortality.
Kaplan-Meier plots were used to evaluate the association
between sleep-disordered breathing severity and mortality. Propor-
tional hazards regression models were then constructed to calculate
unadjusted as well as adjusted relative hazard ratios for mortality.
Age, sex, race, smoking status, body mass index (BMI), and waist
girth were considered as covariates individually and in combination.
Age and BMI were modeled as linear terms in the primary models.
Quadratic or categorical terms for age and BMI were also examined
and were found to not alter model fit or significantly change the
parameter estimates for the AHI. To account for potential
confounding from preexisting medical conditions, prevalent hyper-
tension, blood pressure, cardiovascular disease (angina, heart
failure, myocardial infarction, stroke, and coronary revasculariza-
tion), diabetes, and smoking status (current, former, or never) at
enrollment were included as covariates. Because severity of sleep-
disordered breathing and mortality varied significantly as a function
of sex and age, additional analyses examined interactions by testing
the cross-product terms between AHI, age, and sex. Stratified
models were then constructed to examine differential effects of
sleep-disordered breathing on mortality by sex and age. In the final
stratified models, age was dichotomized as #70 and .70 y. The
cutoff point of 70 y was based on sensitivity analyses that showed a
statistically significant interaction between sleep-disordered breath-
ing severity and age. Finally, the dose–response relationship
between AHI and mortality was examined with regression spline
analyses. All analyses were conducted using SAS 9.0 (SAS Institute,
Cary, NC) and the R statistical package (http://www.r-project.org).
Results
The analysis cohort included 6,294 participants (53.3%
women), which excluded 147 who reported treatment with
positive airway pressure, an oral appliance, supplemental oxygen,
or an open tracheostomy after the baseline visit. As expected, older
age, male sex, minority race, BMI, and central adiposity were
associated with increasing severity of sleep-disordered breathing
(Table 1). Among men, 42.9% did not have sleep-disordered
Table 1. Baseline characteristics, mortality, and follow-up times of the Sleep Heart Health Study cohort by apnea-hypopnea index
(AHI) category.
Category Subcategory
All Participants
N=6,294
AHI,5.0
N=3,429
AHI: 5.0–14.9
N=1,797
AHI: 15.0–29.9
N=727
AHI$30.0
N=341
Age, years 62.9 (11.0) 61.3 (11.1) 64.8 (10.6) 65.1 (10.5) 64.6 (10.7)
BMI, kg/m2 28.4 (5.3) 27.0 (4.5) 29.5 (5.3) 30.7 (5.8) 32.1 (6.1)
Waist girth, cm 98.1 (16.7) 93.9 (15.3) 101.0 (13.0) 105.3 (18.6) 109.7 (25.7)
Neck circumference, cm 37.9 (4.2) 36.5 (3.9) 38.9 (3.9) 40.1 (4.1) 41.2 (4.1)
Sex, % Women 53.3 63.2 45.7 36.5 29.0
Men 46.7 36.8 54.3 63.5 71.0
Race,% White 76.6 77.5 76.4 74.4 73.0
African-American 8.1 8.3 7.1 8.5 10.0
Native American 9.5 7.7 11.2 12.4 12.0
Hispanic 4.4 4.9 3.8 4.1 4.1
Other 1.4 1.6 1.5 0.6 0.9
Smoking Status, % Never 46.0 48.0 43.7 44.5 41.9
Former 42.6 38.3 47.7 45.8 52.2
Current 11.4 13.7 8.6 9.7 5.9
Hypertension, % 52.4 46.5 57.9 60.0 66.2
Diabetes, % 10.6 8.0 12.4 15.6 16.9
Cardiovascular diseasea, % 18.4 14.1 21.7 25.8 28.4
Deaths, % 16.6 13.9 17.8 22.7 25.2
Follow-up time, person-years 51,523 28,326 14,703 5,823 2,670
Mortality rate, per 1,000 person-years 20.3 16.8 21.7 28.3 32.2
p,0.0001 for comparisons of age, BMI, waist girth, neck circumference, gender, race, smoking status, hypertension, diabetes, and cardiovascular disease across AHI
categories using x2 and analysis of variance to compare categorical and continuous variables, respectively. Values represent mean (standard deviation) or percentage.
aCardiovascular disease defined as presence of angina, heart failure, myocardial infarction, stroke, or any coronary revascularization procedure.
doi:10.1371/journal.pmed.1000132.t001
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breathing, 33.2% had mild disease, 15.7% had moderate disease,
and 8.2% had severe disease. In women, the corresponding
percentages were 64.7%, 24.5%, 7.9%, and 3.0%, respectively.
Prevalent hypertension, diabetes, and cardiovascular disease were
more common in individuals with moderate to severe sleep-
disordered breathing than those with mild or no sleep-disordered
breathing. In total, the cohort accumulated 51,523 person–years
of observation with an average follow-up duration of 8.2 y. Of the
analysis cohort, 1,047 participants (460 women) died during
follow-up, yielding a crude mortality rate of 20.3 deaths per 1,000
person-years (95% CI: 19.1–21.6). Men had a higher mortality
rate than women (24.8 versus 16.5 per 1,000 person-years,
p,0.0001; x2 = 42.3) despite similar age and BMI distributions.
Mortality rates per 1,000 person–years in the full cohort varied
with the AHI category as follows: no sleep-disordered breathing
(16.8; 95% CI: 15.4–18.4), mild disease (21.7; 95% CI: 19.4–24.2),
moderate disease (28.3; 95% CI: 24.3–33.0), and severe disease
(32.2; 95% CI: 26.0–39.8).
Figure 1 shows the Kaplan-Meier survival curves across the four
AHI categories. Because sleep-disordered breathing severity was
different in men and women, multivariable proportional hazards
regression models were constructed initially for the full sample and
then stratified by sex (Table 2). Three nested models were used to
assess incremental effects of various confounding covariates on the
association between the AHI and mortality. The base model
included AHI as a categorical variable with adjustments for age,
sex, and race. The second model added BMI to the base model.
The third model added smoking status and prevalent medical
conditions as the final set of covariates. Analysis using the full
cohort revealed a positive and independent association between
sleep-disordered breathing and mortality. Compared to the
reference group without sleep-disordered breathing, the fully
adjusted hazard ratios for mild, moderate, and severe disease were
0.93 (95% CI: 0.80–1.08), 1.17 (95% CI: 0.97–1.42), and 1.46
(95% CI: 1.14–1.85), respectively. Inclusion of cholesterol levels as
an additional covariate did not change the hazard ratios relating
sleep-disordered breathing to mortality. Stratified analyses by sex
showed that AHI was associated with mortality in men but not
women (Table 2).
Across all multivariable models, age had a substantial impact on
mortality. The two-way interaction between AHI and age was
statistically significant (p,0.005; x2 = 8.0). In the fully adjusted
model for men younger than 70 years, the hazard ratios for mild,
Table 2. Adjusted hazard ratios (95% confidence intervals) for all-cause mortality associated with sleep-disordered breathing in
the Sleep Heart Health Study.
Apnea–Hypopnea Index (Events/h) N Person–Years Deaths Mortality Ratea Model 1b Model 2c Model 3d
All participantse
,5.0 3,429 28,326 477 16.8 1.00 1.00 1.00
5.0–14.9 1,797 14,703 319 21.7 0.90 (0.78–1.04) 0.93 (0.80–1.07) 0.93 (0.80–1.08)
15.0–29.9 727 5,823 165 28.3 1.16 (0.97–1.39) 1.20 (1.00–1.44) 1.17 (0.97–1.42)
$30.0 341 2,670 86 32.2 1.30 (1.03–1.64) 1.38 (1.08–1.75) 1.46 (1.14–1.86)
Men
,5.0 1,262 10,275 216 21.0 1.00 1.00 1.00
5.0–14.9 976 7,873 193 24.5 0.94 (0.78–1.15) 0.99 (0.81–1.20) 1.01 (0.83–1.24)
15.0–29.9 462 3,651 114 31.2 1.23 (0.98–1.54) 1.30 (1.03–1.64) 1.27 (1.00–1.65)
$30.0 242 1,872 64 34.2 1.30 (0.98–1.72) 1.42 (1.06–1.90) 1.54 (1.15–2.08)
Women
,5.0 2,167 18,050 261 14.5 1.00 1.00 1.00
5.0–14.9 821 6,830 126 18.5 0.84 (0.68–1.04) 0.85 (0.68–1.06) 0.83 (0.66–1.04)
15.0–29.9 265 2,171 51 23.5 1.05 (0.77–1.42) 1.06 (0.78–1.43) 1.01 (0.73–1.38)
$30.0 99 798 22 27.6 1.34 (0.86–2.07) 1.37 (0.88–2.13) 1.40 (0.89–2.22)
aCrude mortality rate per 1,000 person-years.
bModel 1: Adjusted for age (continuous) and race.
cModel 2: Adjusted for covariates of model 1 and body mass index (continuous).
dModel 3: Adjusted for covariates of model 2, smoking status (never, former, current), systolic and diastolic blood pressure, prevalent hypertension, diabetes, and
cardiovascular disease.
eSex was included as a covariate in each of the three models based on all participants.
doi:10.1371/journal.pmed.1000132.t002
Figure 1. Kaplan-Meier survival curves across categories of the
apnea–hypopnea index (AHI).
doi:10.1371/journal.pmed.1000132.g001
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moderate, and severe sleep-disordered breathing were 1.24 (95%
CI: 0.90–1.71), 1.45 (95% CI: 0.98–2.14), and 2.09 (95% CI: 1.31–
3.33), respectively (Table 3). In contrast, sleep-disordered breathing
was not associated with mortality in men over 70 years of age. For
women, sleep-disordered breathing severity was not associated with
mortality in either age group (Table 3). Interestingly, age and sex-
stratified spline regression models showed that the mortality risk in
men aged 40–70 y increased linearly from relatively low AHI values
without evidence of a specific threshold for excess risk (Figure 2).
The lack of a significant association in the younger women is likely
due to the limited numbers of participants with severe disease.
Analyses were undertaken to assess whether the arousal
frequency, the central apnea index, and measures of sleep-related
hypoxemia (i.e., TST90) were associated with mortality. Regardless
of age and other covariates, arousal frequency and the central
apnea index (Tables 4 and 5) were not associated with mortality in
men or women irrespective of whether these measures were
modeled continuously or categorically. However, TST90 was a
significant predictor of mortality in men less than 70 y in age, even
after adjusting for age, race, smoking status, BMI, systolic and
diastolic blood pressure, AHI, prevalent hypertension, diabetes,
and cardiovascular disease. Compared to the first three quartiles
(TST90#2.70%), younger men in the fourth quartile
(TST90.2.70%) had an adjusted hazard ratio of 1.83 (95% CI:
1.31–2.52) for mortality. In older men and women of both age
categories, TST90 was not associated with mortality.
The association between sleep-disordered breathing and CAD-
specific mortality was further examined in the 220 deaths that
occurred during follow-up. As before, sex-stratified multivariable
analyses were undertaken. However, given the limited number of
events, further stratification by age was not possible. In men, an
AHI$15 events/h had a fully adjusted hazard ratio of 1.69 (95%
CI: 1.13–2.52) for CAD-related death. In women, an association
was not identified between sleep-disordered breathing and CAD-
related deaths.
Discussion
Using a prospective cohort study, which included middle-aged
and older adults from several United States communities, we
examined the independent association between sleep-disordered
breathing and mortality. The results of this study demonstrate
that, independent of several confounding variables, sleep-disor-
dered breathing was associated with all-cause and cardiovascular
disease–related mortality. The association was most apparent in
men aged 40–70 y with severe disease (AHI$30 events/h). The
degree of sleep-related hypoxemia was found to be independently
associated with mortality, whereas the arousal frequency and the
central sleep apnea index were not.
The question of whether sleep-disordered breathing decreases
survival has great clinical and public health significance. To date, a
number of studies on clinical populations have been carried out on
the association between sleep-disordered breathing and mortality
and the findings have been conflicting [3–13]. Discrepancies
across the available clinic-based studies have resulted, in part, from
inconsistencies in methods used to assess breathing abnormalities
Table 3. Adjusted hazard ratios (95% confidence intervals) for all-cause mortality associated with sleep-disordered
breathing,stratified by sex and age in the Sleep Heart Health Study.
Apnea–Hypopnea Index (Events/h) N Person–Years Deaths Mortality Ratea Model 1b Model 2c Model 3d
Men #70 y
,5.0 985 8,220 91 11.1 1.00 1.00 1.00
5.0–14.9 694 5,697 82 14.4 1.10 (0.81–1.48) 1.16 (0.85–1.58) 1.24 (0.90–1.71)
15.0–29.9 322 2,623 47 17.9 1.37 (0.96–1.95) 1.44 (1.00–2.08) 1.45 (0.98–2.14)
$30.0 168 1,355 28 20.7 1.67 (1.09–2.55) 1.88 (1.19–2.95) 2.09 (1.31–3.33)
Men .70 y
,5.0 277 2,055 125 60.8 1.00 1.00 1.00
5.0–14.9 282 2,176 111 51.0 0.86 (0.67–1.11) 0.89 (0.69–1.16) 0.92 (0.70–1.20)
15.0–29.9 140 1,029 67 65.1 1.18 (0.87–1.58) 1.25 (0.92–1.70) 1.23 (0.90–1.68)
$30.0 74 517 36 69.6 1.16 (0.80–1.69) 1.25 (0.85–1.83) 1.27 (0.86–1.86)
Women #70 y
,5.0 1641 13,902 90 6.5 1.00 1.00 1.00
5.0–14.9 527 4,448 40 9.0 1.00 (0.68–1.45) 0.99 (0.66–1.47) 0.97 (0.64–1.48)
15.0–29.9 161 1,350 14 10.4 1.11 (0.63–1.96) 1.12 (0.62–2.02) 1.15 (0.63–2.11)
$30.0 63 537 8 14.9 1.73 (0.84–3.58) 1.75 (0.82–3.74) 1.76 (0.77–3.95)
Women .70 y
,5.0 526 4,149 171 41.2 1.00 1.00 1.00
5.0–14.9 294 2,382 86 36.1 0.77 (0.60–1.00) 0.78 (0.60–1.02) 0.77 (0.58–1.00)
15.0–29.9 104 821 37 45.1 0.98 (0.68–1.40) 0.99 (0.69–1.42) 0.89 (0.61–1.31)
$30.0 36 261 14 53.6 1.09 (0.62–1.89) 1.10 (0.63–1.92) 1.14 (0.65–2.01)
aCrude mortality rate per 1,000 person years.
bModel 1: Adjusted for age (continuous) and race.
cModel 2: Adjusted for covariates of model 1 and body mass index (continuous).
dModel 3: Adjusted for covariates of model 2, smoking status (never, former, current), systolic and diastolic blood pressure, prevalent hypertension, diabetes, and
cardiovascular disease.
doi:10.1371/journal.pmed.1000132.t003
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during sleep, differences in disease definition, and variable
attention to potential confounding factors. In one of the earliest
case series of 1,620 patients with sleep-disordered breathing, Lavie
et al. [10] showed that an apnea index of more than 30 events/h
was associated with all-cause mortality in young and middle-aged
men. While this study highlighted the importance of sleep-
disordered breathing as a risk factor for mortality, its findings are
limited by the exclusion of women, the lack of consideration of
treatment effects, and the concern for referral bias that is inherent
in clinical populations. Although a subsequent report, which
included 14,589 male patients from the same clinical center,
confirmed the earlier observation that sleep-disordered breathing
is independently associated with mortality, all of the methodolog-
ical concerns remained [17].
Several groups have also examined the association of sleep-
disordered breathing and mortality in community or population
cohorts. Unfortunately, even in these studies, the use of snoring as a
surrogate for sleep-disordered breathing [12] or the assessment of
only elderly participants [11] limits inferences regarding the
association between sleep-disordered breathing and mortality for
the general population. Recent findings from the Wisconsin Sleep
Cohort and the Busselton Sleep Cohort studies, which have
incorporated objective measures of sleep-disordered breathing in
general population samples, show an independent association
between sleep-disordered breathing and all-cause mortality
[20,21]. In the Wisconsin study, the fully adjusted hazard ratio for
all-cause mortality comparing people with severe disease to those
without disease (AHI$30 events/h versus. ,5 events/h) was 2.7
(95% CI: 1.3–5.7). Cardiovascular disease-related mortality in the
Wisconsin study was also higher in people with severe disease than
those without disease (hazard ratio: 5.2; 95% CI: 1.4–19.2). While
the Busselton study did not examine cause-specific mortality, it too
found that moderate-to-severe sleep-disordered breathing was
associated with all-cause mortality with an adjusted hazard ratio
of 6.2 (95% CI: 2.0–19.4). Although results from both of these
studies are congruent with each other and with the results presented
herein, the relatively small number of participants with moderate-
to-severe sleep-disordered breathing and the limited number of
deaths in either cohort (33 in the Busselton cohort and 80 in the
Wisconsin cohort) limited the ability to assess effect modification
by age and sex and characterize dose–response associations be-
tween sleep-disordered breathing and mortality. Furthermore, the
potential associations between sleep-related oxyhemoglobin desat-
uration, recurrent arousals from sleep, occurrence of central sleep
apneas, and mortality were not assessed by either study.
The Sleep Heart Health Study adds to the available evidence by
demonstrating that sleep-disordered breathing is associated with
mortality and that this association is potentially mediated by the
degree of sleep-related intermittent hypoxemia. The association
with mortality was observed in only those participants with an
AHI$30 events/h. The current study also finds that excess
mortality is most apparent in men aged #70 y. Although a similar
association was also observed in younger women, particularly with
severe disease (AHI$30 events/h), the adjusted hazard ratios did
not reach statistical significance. Because of the limited number of
deaths in younger women with moderate to severe disease in our
Figure 2. Spline regression models relating the apnea–hypopnea index (AHI) to the log(relative hazard) for all-cause mortality in
men and women stratified by age (#70 and .70 y).
doi:10.1371/journal.pmed.1000132.g002
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study, we cannot exclude an independent association between
sleep-disordered breathing and mortality in women. Additional
research is needed to determine whether a longer period of follow-
up with a sufficient number of diseased people would uncover
whether sleep-disordered breathing is independently related to
mortality in women. Furthermore, the negative finding in older
adults (age .70 y) should not obviate the clinical concern for
identifying and treating sleep-disordered breathing in this
subgroup. With increasing age, the likelihood of death from other
causes rises so that quantifying the potential association between
sleep-disordered breathing and mortality becomes more difficult.
It is also possible that, compared to younger or middle-aged adults,
sleep-disordered breathing in the older adults may be distinct in its
impact on clinical outcomes.
Several potential mechanisms could underlie the higher
mortality risk in sleep-disordered breathing. A number of studies
over the last decade, including the Sleep Heart Health Study
[23,24], have shown that sleep-disordered breathing is associated
with hypertension, CAD, congestive heart failure, and stroke [22].
Sleep-disordered breathing has also been implicated as a risk
factor for insulin resistance and type 2 diabetes mellitus [29].
Although many of these consequences have been documented in
cross-sectional analyses, several lines of evidence indicate that
sleep-disordered breathing may be a causal factor. Perhaps the
most persuasive evidence is that treatment with positive airway
pressure improves blood pressure [30,31] and may decrease
cardiovascular events [18]. In addition, there are data suggesting
that sleep-disordered breathing can shift the temporal vulnerabil-
ity for sudden cardiac death [32]. In the absence of sleep-
disordered breathing, the greatest risk for sudden cardiac death is
between 6 A.M. and 11 A.M. However, in patients with sleep-
disordered breathing, more than half of sudden cardiac deaths
occur between 10 P.M. and 6 A.M., suggesting that the associated
hemodynamic and physiologic stress may trigger malignant
arrhythmias. Finally, in addition to cardiovascular mortality,
noncardiovascular causes of death may also contribute to excess
mortality, given that people with sleep-disordered breathing are
more prone to motor vehicle accidents particularly those
associated with personal injury [33].
There are several limitations of the current study that merit
discussion. First, because cause-specific death was only adjudicated
for cardiovascular disease, hypothesis testing regarding mortality
from non-cardiovascular causes was not possible. Second,
measurement error from short-term variability in sleep and
breathing patterns might have diluted the mortality risk, as only
one night of recording was used to assess disease severity.
However, previous work on night-to-night variability on sleep
and breathing patterns has shown that one night of recording
provides a reasonably accurate estimate of sleep-disordered
breathing severity [34]. Third, a number of the potentially
confounding covariates (e.g., smoking status) were obtained by self-
report. Nonetheless, in all probability, any bias in self-reported
data is likely to be unrelated to the abnormalities on the sleep
study and thus would not lead to biased estimates of mortality risk.
Fourth, because the Sleep Heart Health Study participants were
recruited from ongoing epidemiological studies of cardiovascular
and respiratory disease, survival bias may have contributed to
some of our findings on sleep-disordered breathing and mortality,
particularly in older participants. Finally, it is important to
recognize that the threshold used to present the age-stratified
results (#70 versus .70 y) was based on sensitivity analyses that
examined several different age cutoff points. Multiple examina-
tions of any data can lead to identification of statistically significant
findings just based on chance. Thus, while the Sleep Heart Health
Study data indicate a differential relation between sleep-disordered
breathing and mortality in younger and older participants, the age
Table 5. Adjusted hazard ratios (95% confidence intervals) for
the association between the central apnea index and all-cause
mortality stratified by sex and age.
Central Apnea Index
(Events/h) Model 1a Model 2b Model 3c
All participantsd
,0.26 1.00 1.00 1.00
$0.26 0.99 (0.85–1.16) 0.99 (0.84–1.15) 1.00 (0.86–1.18)
Men
,0.44 1.00 1.00 1.00
$0.44 1.15 (0.95–1.41) 1.15 (0.95–1.41) 1.16 (0.94–1.42)
Women
,0.16 1.00 1.00 1.00
$0.16 1.10 (0.87–1.40) 1.10 (0.87–1.41) 1.08 (0.84–1.39)
aModel 1: Adjusted for age (continuous) and race. Hazard ratios were derived
comparing the lower three quartiles to the fourth quartile of the central apnea
index.
bModel 2: Adjusted for covariates of model 1 (except sex) and body mass index
(continuous).
cModel 3: Adjusted for covariates of model 2 and smoking status (never, former,
current), hypertension, diabetes, and cardiovascular disease.
dSex was included as a covariate in each of the three models based on all
participants.
doi:10.1371/journal.pmed.1000132.t005
Table 4. Adjusted hazard ratios (95% confidence intervals) for
the association between quartiles of arousal frequency and
all-cause mortality in the Sleep Heart Health Study.
Arousal Frequency
(Events/h) Model 1a Model 2b Model 3c
All participantsd
,12.0 1.00 1.00 1.00
12.0–16.7 0.84 (0.70–1.02) 0.84 (0.70–1.05) 0.86 (0.70–1.05)
16.8–23.5 0.98 (0.82–1.17) 0.98 (0.82–1.18) 0.97 (0.80–1.17)
$23.5 0.98 (0.82–1.16) 0.99 (0.83–1.18) 0.98 (0.82–1.17)
Men
,13.7 1.00 1.00 1.00
13.7–18.7 0.99 (0.77–1.27) 1.00 (0.78–1.29) 1.00 (0.77–1.29)
18.8–25.8 1.11 (0.87–1.41) 1.12 (0.88–1.43) 1.17 (0.91–1.50)
$25.9 1.11 (0.88–1.41) 1.15 (0.91–1.46) 1.14 (0.89–1.45)
Women
,10.8 1.00 1.00 1.00
10.9–15.0 0.84 (0.63–1.12) 0.84 (0.63–1.13) 0.88 (0.66–1.19)
15.1–21.2 0.93 (0.71–1.22) 0.94 (0.72–1.23) 0.89 (0.67–1.17)
$21.3 0.88 (0.68–1.14) 0.88 (0.68–1.15) 0.90 (0.68–1.17)
aModel 1: Adjusted for age (continuous) and race.
bModel 2: Adjusted for covariates of model 1 and body mass index
(continuous).
cModel 3: Adjusted for covariates of model 2 and smoking status (never, former,
current), hypertension, diabetes, and cardiovascular disease.
dSex was included as a covariate in each of the three models based on all
participants.
doi:10.1371/journal.pmed.1000132.t004
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threshold of 70 years should not be overinterpreted. These
limitations notwithstanding, the current study also has several
strengths including the longitudinal assessment of a large
community sample with careful characterization of sleep and
breathing abnormalities, comprehensive assessment of key covar-
iates and outcomes, and analytic consideration of effect modifi-
cation by age and sex.
In conclusion, the Sleep Heart Health Study shows that sleep-
disordered breathing is an independent predictor of mortality and
that this association is not attributable to age, obesity, or other
chronic medical conditions. Although the degree of nocturnal
hypoxemia was an independent predictor of mortality, arousal
frequency and occurrence of central apneas were not. Given the
high and likely increasing prevalence of sleep-disordered breathing
in the general population, additional research in the form of
randomized clinical trials should be undertaken to assess if
treatment can reduce premature mortality associated with this
common and chronic disorder.
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Editors’ Summary
Background. About 1 in 10 women and 1 in 4 men have a
chronic condition called sleep-disordered breathing
although most are unaware of their problem. Sleep-
disordered breathing, which is commonest in middle-aged
and elderly people, is characterized by numerous, brief
(10 second or so) interruptions of breathing during sleep.
These interruptions, which usually occur when relaxation of
the upper airway muscles decreases airflow, lower the level
of oxygen in the blood and, as a result, affected individuals
are frequently aroused from deep sleep as they struggle to
breathe. Symptoms of sleep-disordered breathing include
loud snoring and daytime sleepiness. Treatments include
lifestyle changes such as losing weight (excess fat around the
neck increases airway collapse) and smoking cessation.
Affected people can also use special devices to prevent
them sleeping on their backs, but for severe sleep-
disordered breathing, doctors often recommend
continuous positive airway pressure (CPAP), a machine that
pressurizes the upper airway through a face mask to keep it
open.
Why Was This Study Done? Sleep-disordered breathing is
a serious condition. It is associated with several adverse
health conditions including coronary artery disease
(narrowing of the blood vessels that supply the heart, a
condition that can cause a heart attack) and daytime
sleepiness that can affect an individual’s driving ability. In
addition, several clinic- and community-based studies
suggest that sleep-disordered sleeping may increase a
person’s risk of dying. However, because these studies
have been small and have often failed to allow for other
conditions and characteristics that affect an individual’s risk
of dying (‘‘confounding factors’’), they provide inconsistent
or incomplete information about the potential association
between sleep-disordered breathing and the risk of death. In
this prospective cohort study (part of the Sleep Heart Health
Study, which is researching the effects of sleep-disordered
breathing on cardiovascular health), the researchers examine
whether sleep-disordered breathing is associated with all-
cause mortality (death from any cause) in a large community
sample of adults. A prospective cohort study is one in which
a group of participants is enrolled and then followed forward
in time (in this case for several years) to see what happens to
them.
What Did the Researchers Do and Find? At enrollment,
the study participants—more than 6,000 people aged 40
years or older, none of whom were being treated for sleep-
disordered breathing—had a health examination. Their
night-time breathing, sleep patterns, and blood oxygen
levels were also assessed and these data used to calculate
each participant’s apnea-hypopnea index (AHI)—the number
of apneas and hypopneas per hour. During the study follow-
up period, 1,047 participants died. Compared to participants
without sleep-disordered sleeping, participants with severe
sleep-disordered breathing (an AHI of $30) were about one
and a half times as likely to die from any cause after
adjustment for potential confounding factors. People with
milder sleep-disordered breathing did not have a statistically
significant increased risk of dying. After dividing the
participants into subgroups according to their age and sex,
men aged 40–70 years with severe sleep-disordered
breathing had a statistically increased risk of dying from
any cause (twice the risk of men of a similar age without
sleep-disordered breathing). Finally, death from coronary
artery disease was also associated with sleep-disordered
breathing in men but not in women.
What Do These Findings Mean? These findings indicate
that sleep-disordered breathing is associated with an
increased risk of all-cause mortality, particularly in men
aged 40–70 years, even after allowing for known
confounding factors. They also suggest that the increased
risk of death is specifically associated with coronary artery
disease although further studies are needed to confirm this
finding because it was based on the analysis of a small
subgroup of study participants. Although this study is much
larger than previous investigations into the association
between sleep-disordered breathing and all-cause
mortality, it has several limitations including its reliance on
a single night’s measurements for the diagnosis of sleep-
disordered breathing. Nevertheless, these findings suggest
that clinical trials should now be started to assess whether
treatment can reduce the increased risk of death that seems
to be associated with this common disorder.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000132.
N The US National Heart Lung and Blood Institute has
information (including a video) about sleep-disordered
breathing (sleep apnea) (in English and Spanish)
N The UK National Heath Service also provides information
for patients about sleep apnea
N MedlinePlus provides links to further information and
advice about sleep-disordered breathing (in English and
Spanish)
N More information on the Sleep Heart Health Study is
available
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